A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study from researchers in the Perelman School of Medicine at the University ...

A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical ...

Molecular Partners' DARPin platform shows promise, but future funding is uncertain. Learn why MOLN stock could be a risky, ...

PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

The following is a summary of “Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation,” published in the December ...

A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study from researchers in the Perelman School of Medicine at the University ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

在该研究中，陆佩华院长带领团队创新性地采用基于纳米抗体的CD7 CAR-T治疗急性髓系白血病，研究结果不仅在肿瘤杀伤力和安全性上取得了显著进展，更为难治复发急性髓系白血病的治疗开辟了新路径。

Novel CD37 antibody-drug conjugate shows promise in targeting the Achilles’ heel of acute myeloid leukemia cells.

Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product s ...

The study highlights poor outcomes for leukaemia patients with a history of myelodysplastic syndrome treatment and related ...